基线肠道菌群预测伊匹木单抗治疗的转移性黑色素瘤患者的临床反应和结肠炎
该前瞻性研究纳入26例接受伊匹木单抗治疗的转移性黑色素瘤患者,采用16S rRNA基因测序分析基线及每次输注前的粪便菌群,并对外周血淋巴细胞免疫表型进行研究。结果显示,基线肠道菌群以拟杆菌属为主(B簇,n=10)与以粪杆菌属及其他厚壁菌门为主(A簇,n=12)的患者相比,A簇患者无进展生存期更长(P=0.0039),总生存期有延长趋势(P=0.051)。基线菌群富含粪杆菌属及其他厚壁菌门与伊匹木单抗的良好临床反应及更频繁发生的结肠炎相关。
要点
- 基线肠道菌群富含粪杆菌属及其他厚壁菌门与伊匹木单抗治疗转移性黑色素瘤的临床反应相关。
- 基线菌群以粪杆菌属为主的患者无进展生存期较以拟杆菌属为主者更长(P=0.0039)。
- 基线菌群富含粪杆菌属及其他厚壁菌门与伊匹木单抗诱导的结肠炎更频繁发生相关。
核心结论
- 基线肠道菌群富含粪杆菌属及其他厚壁菌门与伊匹木单抗治疗转移性黑色素瘤的良好临床反应及更频繁发生的伊匹木单抗诱导的结肠炎相关。
研究设计与样本
- 前瞻性纳入26例接受伊匹木单抗治疗的转移性黑色素瘤患者。
- 采用16S rRNA基因测序评估基线及每次伊匹木单抗输注前的粪便菌群组成,并基于菌群模式对患者进行聚类。
- 同步研究外周血淋巴细胞免疫表型。
主要发现
- 与基线菌群以拟杆菌属为主(B簇,n=10)的患者相比,基线菌群富含粪杆菌属及其他厚壁菌门(A簇,n=12)的患者无进展生存期更长(P=0.0039),总生存期有延长趋势(P=0.051)。
- 多数基线结肠炎相关系统型与厚壁菌门相关(如普拉梭菌和Gemmiger formicilis的近缘菌),而未发现属于拟杆菌门的结肠炎相关系统型。
- 外周血调节性T细胞比例较低与A簇、长期临床获益及结肠炎相关。
- 在粪杆菌属驱动的A簇患者中,伊匹木单抗诱导CD4+ T细胞上诱导性T细胞共刺激分子表达更高,血清CD25升高更明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ipilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic melanoma (MM) but can induce immune-related adverse events, including enterocolitis. We hypothesized that baseline gut microbiota could predict ipilimumab anti-tumor response and/or intestinal toxicity. PATIENTS AND METHODS: Twenty-six patients with MM treated with ipilimumab were prospectively enrolled. Fecal microbiota composition was assessed using 16S rRNA gene sequencing at baseline and before each ipilimumab infusion. Patients were further clustered based on microbiota patterns. Peripheral blood lymphocytes immunophenotypes were studied in parallel. RESULTS: A distinct baseline gut microbiota composition was associated with both clinical response and colitis. Compared with patients whose baseline microbiota was driven by Bacteroides (cluster B, n = 10), patients whose baseline microbiota was enriched with Faecalibacterium genus and other Firmicutes (cluster A, n = 12) had longer progression-free survival (P = 0.0039) and overall survival (P = 0.051). Most of the baseline colitis-associated phylotypes were related to Firmicutes (e.g. relatives of Faecalibacterium prausnitzii and Gemmiger formicilis), whereas no colitis-related phylotypes were assigned to Bacteroidetes. A low proportion of peripheral blood regulatory T cells was associated with cluster A, long-term clinical benefit and colitis. Ipilimumab led to a higher inducible T-cell COStimulator induction on CD4+ T cells and to a higher increase in serum CD25 in patients who belonged to Faecalibacterium-driven cluster A. CONCLUSION: Baseline gut microbiota enriched with Faecalibacterium and other Firmicutes is associated with beneficial clinical response to ipilimumab and more frequent occurrence of ipilimumab-induced colitis.
引用
- Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017. PMID: 28368458. doi:10.1093/annonc/mdx108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。